Ann: Quarterly Report and Appendix 4C with appendix, page-2

Ticking all boxes as far as I can see. Plenty of cash in hand for the next set of trials, with a very low market cap of 81 million, 34 mill cash

(Invex’s proposed preclinical and human pharmacokinetic approach was acceptable to both EMA and FDA)

(Invex to optimise the registration strategy for both EU and US over the coming weeks)

Everything is on track, and I see the recent pull back as a great chance to top up. Not to forget this team has no intentions to take this to market, it’s a straight out buy from a large pharmaceutical company when the time is right. AIMHO